{"id":"bcx7353-capsules","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Nasopharyngitis"}]},"_chembl":{"chemblId":"CHEMBL5189739","moleculeType":"Small molecule","molecularWeight":"562.57"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BCX7353 inhibits Factor XIIa-driven contact system activation by blocking plasma kallikrein, thereby reducing excessive bradykinin production. This mechanism is intended to prevent the inflammatory cascade and vascular permeability changes characteristic of hereditary angioedema (HAE). By targeting the upstream contact pathway rather than downstream bradykinin receptors, it may provide broader suppression of HAE attacks.","oneSentence":"BCX7353 is a selective inhibitor of plasma kallikrein that reduces bradykinin generation in the contact system pathway.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:46.197Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hereditary angioedema (HAE) with C1-inhibitor deficiency or dysfunction"}]},"trialDetails":[{"nctId":"NCT05453968","phase":"PHASE3","title":"Berotralstat Treatment in Children With Hereditary Angioedema","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioCryst Pharmaceuticals","startDate":"2022-10-25","conditions":"Hereditary Angioedema, Pediatric","enrollment":29},{"nctId":"NCT04933721","phase":"PHASE3","title":"Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies","status":"ENROLLING_BY_INVITATION","sponsor":"BioCryst Pharmaceuticals","startDate":"2021-07-23","conditions":"Hereditary Angioedema, HAE","enrollment":139},{"nctId":"NCT03873116","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in Japan","status":"COMPLETED","sponsor":"BioCryst Pharmaceuticals","startDate":"2018-12-27","conditions":"Hereditary Angioedema, HAE","enrollment":19},{"nctId":"NCT03485911","phase":"PHASE3","title":"Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE","status":"COMPLETED","sponsor":"BioCryst Pharmaceuticals","startDate":"2018-02-06","conditions":"Hereditary Angioedema, HAE","enrollment":121},{"nctId":"NCT03472040","phase":"PHASE2, PHASE3","title":"A Long Term Safety Study of BCX7353 in Hereditary Angioedema","status":"COMPLETED","sponsor":"BioCryst Pharmaceuticals","startDate":"2018-02-16","conditions":"Hereditary Angioedema, HAE, Prophylaxis","enrollment":387},{"nctId":"NCT02870972","phase":"PHASE2","title":"Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema","status":"COMPLETED","sponsor":"BioCryst Pharmaceuticals","startDate":"2016-08","conditions":"Hereditary Angioedema (HAE)","enrollment":75},{"nctId":"NCT04428632","phase":"","title":"Oral Berotralstat Expanded Access Program","status":"APPROVED_FOR_MARKETING","sponsor":"BioCryst Pharmaceuticals","startDate":"","conditions":"Hereditary Angioedema, HAE, Prophylaxis","enrollment":""},{"nctId":"NCT03202784","phase":"PHASE1","title":"A Relative Bioavailability Study of Two Formulations of BCX7353","status":"COMPLETED","sponsor":"BioCryst Pharmaceuticals","startDate":"2017-02-27","conditions":"Hereditary Angioedema","enrollment":24},{"nctId":"NCT02448264","phase":"PHASE1","title":"First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BCX7353 in Healthy Western and Japanese Volunteers","status":"COMPLETED","sponsor":"BioCryst Pharmaceuticals","startDate":"2015-05","conditions":"Hereditary Angioedema","enrollment":122}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Berotralstat"],"phase":"phase_3","status":"active","brandName":"BCX7353 capsules","genericName":"BCX7353 capsules","companyName":"BioCryst Pharmaceuticals","companyId":"biocryst-pharmaceuticals","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BCX7353 is a selective inhibitor of plasma kallikrein that reduces bradykinin generation in the contact system pathway. Used for Hereditary angioedema (HAE) with C1-inhibitor deficiency or dysfunction.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}